Beta-Blockers Are NOT Recommended as First-Line Therapy for Uncomplicated Hypertension
Beta-blockers should not be used as first-line agents for uncomplicated hypertension, particularly in patients ≥60 years of age 1, 2, 3, 4, 5. The most recent ACC/AHA and Hypertension Canada guidelines consistently classify beta-blockers as secondary agents unless compelling indications exist (ischemic heart disease or heart failure).
When Beta-Blockers Should Be Used
Beta-blockers are appropriate in hypertension when:
- Compelling cardiovascular indications exist: Post-myocardial infarction, stable angina, heart failure with reduced ejection fraction (HFrEF), or need for heart rate control 1, 2, 6
- Age <60 years without complications: May be considered as monotherapy in younger patients 5
- Combination therapy: Can be added to first-line agents when blood pressure remains uncontrolled 1, 2
If a Beta-Blocker Must Be Chosen
The best beta-blocker options for hypertension are the cardioselective agents with additional vasodilatory properties:
First Choice: Nebivolol (5-40 mg once daily)
- Induces nitric oxide-mediated vasodilation 1, 2, 3
- Superior hemodynamic profile with beneficial effects on central blood pressure and arterial stiffness 7, 8
- Preferred in patients with diabetes due to neutral metabolic effects 9
- Highest beta-1 selectivity among available agents 9
Second Choice: Bisoprolol (2.5-10 mg once daily) or Metoprolol Succinate (50-200 mg once daily)
- Cardioselective agents preferred in HFrEF 1, 2, 4
- Better tolerated than non-selective agents
- Preferred over metoprolol tartrate due to once-daily dosing 1
Third Choice: Carvedilol (12.5-50 mg twice daily)
- Combined alpha- and beta-receptor blockade 1, 2
- Preferred specifically in HFrEF 1, 4
- Requires twice-daily dosing, which may reduce adherence
Agents to Avoid
Atenolol should be avoided - Most negative data regarding beta-blockers in hypertension comes from atenolol-based studies 7, 8, 10. It shows:
- Inferior stroke prevention compared to other antihypertensives
- Poor central blood pressure reduction
- Adverse metabolic effects
- Twice-daily dosing requirement 1, 2
Beta-blockers with intrinsic sympathomimetic activity (acebutolol, penbutolol, pindolol) should generally be avoided, especially in patients with ischemic heart disease or heart failure 1, 3, 4.
Critical Considerations
- Bronchospastic disease: If beta-blocker required, use cardioselective agents (betaxolol, bisoprolol, metoprolol, nebivolol) 1, 2
- Never combine with non-dihydropyridine calcium channel blockers (diltiazem, verapamil) due to increased risk of bradycardia and heart block 1, 2
- Always taper when discontinuing - abrupt cessation can precipitate hypertensive crisis or cardiac events 1, 2, 4
- Peripheral artery disease and COPD are no longer contraindications for cardioselective agents 11
The Bottom Line
For uncomplicated hypertension, start with thiazide/thiazide-like diuretics, ACE inhibitors, ARBs, or long-acting calcium channel blockers 1, 2, 5, 12. If a beta-blocker is specifically needed due to compelling indications or as add-on therapy, nebivolol is the preferred choice due to its vasodilatory properties and superior hemodynamic profile 9, 7, 8. The widespread inappropriate prescribing of beta-blockers (particularly atenolol) for uncomplicated hypertension remains a significant quality issue in clinical practice 13.